Abstract Platelet adhesion and aggregation during hemostasis and thrombosis are usually limited to sites where the integrity of the vessel wall is disrupted. The high concentration of platelet agonists within these sites represents a putative control mechanism for targeting platelet activation. Although much has been learned about the intracellular signaling systems controlling platelet activation, our inhibition is due to suppression of GPILb-IIIa activation. In contrast, genistin, an isoflavone compound related to genistein, and acetylsalicylic acid do not affect the tyrosine kinase-signaling pathway, nor do they inhibit GPIIb-IIIa activation induced by strong agonists. On identifying prominent tyrosine kinase substrates in activated platelets, we confirm that several substrates correspond to proteins associated with the cytoskeleton: the 85-kD subunit of phosphatidylinositol 3-kinase, the SH3-containing and actin-associating p85, pp6OYr, and pp125'F. Our data showing that tyrosine kinase activity is required for GPIIb-IIIa activation, together with previous studies indicating that fibrinogen binding to its receptor results in tyrosine phosphorylation of platelet substrates, suggest that a dual regulatory mechanism allows for full platelet response only at sites where both pathways are activated, namely disrupted vessel walls. (Circ Res. 1994;75:172-180.) Key Words * cytoskeleton * glycoprotein lIb-Illa .
Platelet Tyrosine Kinases 4 Integrins are heterodimeric integral membrane glycoproteins that mediate in a ligand-specific manner cellcell and cell-extracellular matrix interactions.5 GPIIbIlla is the most abundant integrin on the surface of platelets,1"2 and it binds fibrinogen, fibronectin, von Willebrand factor, vitronectin, and thrombospondin on the surface of activated thrombocytes. In unactivated platelets, GPIIb-IIIa does not bind to circulating fibrinogen.1"2 Activation of platelets results in an uncharacterized change in GPIIb-IIIa structure, leading to lowering of the dissociation constant (Kd) for its ligands.6 This structural change appears to be intrinsic to the receptor and most likely involves the participation of specific intracellular signaling pathways and possibly cytoskeletal structures. 7 Tyrosine kinases are important signal transducers in many cell types.8 Several transmembrane receptors have tyrosine kinase activity (receptor tyrosine kinases). Platelets do not possess the receptor type of tyrosine kinases but do contain intracellular PTKs. Agonistinduced platelet activation results in tyrosine phosphorylation of numerous platelet proteins.9'10 Receptor occupancy of the activated conformation of GPIIb-IIIa is necessary for functioning of certain PTKs."1 It was previously shown that on the surface of aggregating platelets, the GPIJb-IIIa receptor is able to modulate the activity of cytoplasmic tyrosine kinases, in particular pp125FAK12 and a yet-uncharacterized PTK upstream from pp125`AK.13 Therefore, it is postulated that an active connection exists between the fibrinogen receptor and signaling pathways, particularly those involving tyrosine kinases and their substrates.13 Because agonistinduced activation results in enhanced tyrosine kinase activity and these kinases are signal transducers, we hypothesized that PTKs are necessary for the conformational changes seen in GPIIb-IIIa on activation.
Therefore, we investigated further the role of tyrosine kinase-regulated pathways in the expression of the activated form of GPIIb-IIIa on the surface of platelets.
Using two specific tyrosine kinase inhibitors, genistein (which belongs to the isoflavone family)'4 and AG-18 (which belongs to the tyrphostin family), '5 
Preparation of Platelets
Venipuncture was performed on normal human volunteers with a 19-gauge needle without a tourniquet, the first 5 mL of venous blood was discarded, and then a total 25.5 mL of blood was drawn into a plastic syringe containing 4.5 mL of a citrated buffer (mmol/L: citric acid 38, sodium citrate 74.8, and dextrose 136). For experiments involving the effect of aspirin (acetylsalicylic acid) on platelet tyrosine kinase, volunteers were given 325 mg of enteric-coated aspirin daily for 7 days to allow for maximal platelet cyclooxygenase inhibition.
Platelet isolation was performed at room temperature. Platelet-rich plasma was obtained by centrifugation of the citrated blood at 150g for 15 minutes. To reduce platelet activation induced by in vitro manipulations, PGE1 (1 ,umol/L) was added to the platelet-rich plasma, and the platelets were pelleted by further centrifugation at 450g for 10 minutes. The platelet-poor plasma was removed, and the platelets were rinsed with Tyrode's buffer (mmol/L: NaCl 138, KCl 2.9, NaHCO3 12, Na2HPO4 0.36, glucose 5.5, CaCl2 1.8, and MgCl2 0.49) by gently covering the platelet pellet with 3 mL of Tyrode's buffer and aspirating the buffer without disrupting the cells. The pellet was resuspended in Tyrode's buffer to provide the platelet concentration required for each type of experiments (107 to 10i cells per milliliter).
Platelet Activation
All platelets were studied within 2 hours of phlebotomy. At room temperature, platelets were activated with thrombin (0.25 to 0.5 U/mL), the thrombin receptor activating peptideSer-Phe-Leu-Leu-Arg-Asn (sfllrn, 43 gmol/L), or ADP (20 gmol/L) for various periods of time as indicated. Activation was performed by adding the agonist to the sample, inverting the sample once, and letting the sample rest.
In some experiments, a tyrosine kinase inhibitor (genistein or AG-18) was added to the samples before the addition of agonist. Genistein was suspended in dimethyl sulfoxide and then diluted in Tyrode's buffer by using sonication where indicated. The incubation time and concentration (600 ,umol/L or 162 ,ug/mL) were selected by performing preliminary experiments with serial dilutions of unsonicated genistein. In these conditions, 600 gmol/L genistein corresponds to the lowest concentration that achieved maximum inhibition of tyrosine kinase activity without disrupting the integrity of the cells (assessed by microscopy; see below) within 90 minutes of phlebotomy. AG-18 stock solution was also suspended in dimethyl sulfoxide, and further dilution of the stock solution in Tyrode's buffer required sonication (use of Branson Sonifier probe at levels 3 through 5 until a clear solution was obtained). The tyrosine kinase inhibitor concentrations achieved intracellularly in these conditions were not known and may vary. Therefore, the inhibitor concentrations indicated in the present study correspond to the maximal concentrations that are theoretically achievable inside platelets.
After incubation, the cells were immediately lysed by either boiling in sodium dodecyl sulfate 
Immunoblotting and Immunoprecipitation
The Triton X-100-lysed samples normalized for total protein (3 g/L) were incubated with an antibody (monoclonal antibodies anti-phosphotyrosine, anti-PI3-kinase, anti-pp60'-anti-ppl25FAK, and anti-p85-SH3) at 0.2 to 10 mg/L for 5 minutes and then incubated with saturating amounts of protein A-Sepharose beads (50 to 100 gL of pelleted beads per milliliter). Anti-phosphotyrosine immunoprecipitates were obtained using a monoclonal antibody covalently attached to agarose beads (UBI). Samples were gently rotated for 90 minutes at 4°C. The beads were washed four times in L buffer without Triton X-100 or protease inhibitors and then boiled in 60 gL of SDS buffer for 5 minutes. The samples were analyzed by SDS-polyacrylamide gel electrophoresis by use of 4% to 20% gradient gels.'617 The proteins were transferred onto nitrocellulose membrane, and immunoblots were reacted with specific antibodies at 0.2 mg/L in Tris-buffered saline (TBS, containing 20 mmol/L Tris base [pH 7.6] and 137 mmol/L NaCl) and then with a peroxidase-labeled goat anti-mouse antibody (1 mg/L) in TBS, as previously described.16'17 Immunoblots were developed using the enhanced chemiluminescence system (Amersham Corp). The intensity of individual bands on chemiluminograms was quantified by densitometry.17
Platelet Aggregation
We measured platelet aggregation in whole blood by use of a single-channel impedence meter (Chronolog) and a sample volume of 0.5 mL stirred at 103 rpm.18 Baseline readings were obtained for 20 minutes to document the quiescent state of the platelets, and agonists were then swiftly pipetted into the 174 Circulation Research Vol 75, No 1 July 1994 samples. To study the effect of genistein on platelet aggregation, we measured platelet aggregation in response to 0.5 U/mL thrombin in the presence and absence of a 45-minute pretreatment with 600 pmol/L genistein. For each platelet sample, the effect of genistein was expressed as the ratio of the change in impedance, observed 15 minutes after agonist stimulation of a blood sample pretreated with genistein, to the change in impedance of a nonpretreated sample.
Measurement of Activated GPIIb-IIIa Density Fibrinogen-Binding Assay
This assay is based on the unique ability of activated GPIIb-IIIa to bind fibrinogen in solution on the surface of platelets. Labeling of fibrinogen with FITC, quantification of fibrinogen in solution, and determination of the fluorescein to fibrinogen ratio were performed as reported previously.)9 Platelets (107 cells per milliliter) were suspended in Tyrode's buffer (500 pL) and incubated with FITC-fibrinogen (0.1 mg/mL) with or without an agonist or a tyrosine kinase inhibitor. Samples were analyzed in a fluorescence-activated cell sorter (FACScan, Becton Dickinson), which was calibrated daily for fluorescence by use of Cytofluor fluorescent beads.'9 Data aquisition and processing from 10' cells were carried out on a Hewlett Packard computer with FACSCAN research software (version B). The median channel number was used as the measure of platelet fluorescence intensity.'9 Four concentrations of F1TC calibration beads were used to generate a standard curve, which provided the median channel number as a function of fluorescein equivalents present per bead, which are directly proportional to the number of FITC molecules.'9 With this standard curve and the known fluorescein-to-fibrinogen ratio, we were able to determine the number of FITC-fibrinogen molecules bound per platelet: FITCfibrinogen per platelet=fluorescein equivalents per platelet/ fluorescein equivalents per fibrinogen molecule. '9 PACI-Binding Assay PAC1 is a monoclonal IgM specific for the activated conformation of GPIIb-lIla.20 To detect activated GPIIb-IIIa on the surface of platelets, we used fluorescence-activated flow cytometric analysis of PACI binding to platelets. Platelets ( (Fig 1, lane  2 ) and after activation with thrombin (Fig 1, lane 4) , confirming the strong inhibitory activity of genistein for platelet tyrosine kinases. 2' 22 In the absence of genistein, thrombin stimulation of platelets resulted in the tyrosine phosphorylation of several platelet proteins (Fig 1, lane 3) . The (Fig 3a, panel IV) .
However, this reduction was overcome with time, as progressive recovery of PAC1 binding was observed over the 30 minutes following thrombin stimulation of genistein-treated platelets (Fig 3a, panel V) . The effect of genistein on PAC1 binding was concentration dependent and was more pronounced when the thrombin receptor-activating peptide was used instead of thrombin itself (Fig 3b) . To elucidate the mechanism by which the genistein inhibition of activated GPIIb-IIIa was lost over time, we studied the kinetics of the tyrosine phosphorylation reaction triggered by thrombin in platelets pretreated with genistein (Fig 4) . Immunoblot analysis demonstrated that the reexpression of the activated conformation of GPIIb-IIIa detected by PAC1 assay (Fig 3a) correlated with the progressive resumption in tyrosine phosphorylation of platelet proteins (Fig 4) . Prolonging the duration of platelet exposure to thrombin resulted in an increase in the amount of phosphotyrosine proteins seen in platelet extracts. After 30 minutes of agonist exposure, the amount of phosphotyrosine seen in genistein-treated platelets (Fig 4, lane 6 (Fig 4, lane 1) . Thus, the kinetics of tyrosine kinase activity, and in particular the tyrosine phosphorylation of p110, p95, and p85-SH3, closely paralleled the kinetics of the expression of activated GPIIb-IIa. These data also indicated that the effect of genistein was not to disrupt platelet integrity but instead to reversibly inhibit platelet tyrosine kinase activities and their pathways. The absence of effect of genistin (a compound related to genistein but without tyrosine kinase-inhibitory activity) on GPIIb-IIla activation was consistent with our hypothesis that suppression of GPIIb-IIIa activation by genistein was mediated by the tyrosine kinase-inhibitory effect of this molecule (Fig 3b) We used a battery of antibodies against known platelet proteins that are involved in cytoskeletal reorganization to test whether they correspond to tyrosine kinase substrates in thrombin-activated platelets; these substrates potentially mediate the downregulation of GPIIb-IIIa activation induced by tyrosine kinase inhibitors. pp60Sr ,29 the most abundant PTK in platelets, and pp125FA3o are both associated with focal adhesion actin networks and are clearly phosphorylated on tyrosine after thrombin (or ADP) activation (Fig 6) . This phosphorylation was inhibited by genistein. P13-kinase has also been suspected to participate in actin cytoskeleton reorganization, and its activity greatly increases in response to agonist stimulation of platelets.31,32 The docking p85 subunit of P13-kinase was phosphorylated on tyrosine in response to agonists, and this phosphorylation was inhibited by genistein. Similar results were seen for p85-SH3, a protein whose function is unknown but which contains a putative actin cytoskeleton-binding 
Detection of Tyrosine Kinase Substrates in Permeabilized Platelets
Immunohistochemistry was performed on platelets adhering to collagen-coated coverslips with and without thrombin activation and genistein inhibition to detect the proteins phosphorylated by platelet PTKs (Fig 7) . Thrombin activation resulted in the formation of cellular extensions,34 and these extensions were rich in tyrosine-phosphorylated substrates, considering the relatively small volume of these extensions and the intensity of their staining for phosphotyrosine. These experiments indicated that genistein at the concentration used (600 gmol/L, which was enough to block the phosphorylation on tyrosine of platelet substrates) did not detectably alter platelet integrity, since the adhesion of platelets to collagen-coated coverslips was not abolished by genistein pretreatment. It is possible that extension formation, which requires cytoskeletal reorganization,34 was inhibited by genistein. This effect correlates with the decrease in tyrosine phosphorylation of platelet proteins (Fig 7) . However, immunoeytochemical data are semiquantitative, and additional studies will be necessary to conclude that genistein inhibited the actin response to agonists.
Discussion
We provide evidence that phosphorylation of specific tyrosine kinase substrates in activated platelets is necessary to allow the rapid conformational change of GPIIb-IIJa to occur. Change in GPIIb-IIIa conformation on the platelet surface is necessary for binding to soluble fibrinogen, thus allowing fibrinogen-mediated bridge formation between thrombocytes. Besides being an adhesive molecule, GPIIb-lIIa receptor also functions as a signal modulator. Recent publications suggest that GPIIb-IIIa cross-linking by fibrinogen (one fibrin- of Src is known to inhibit pp605`tyrosine kinase activity.8 39 It is likely that the activity of pp60r( is regulated by the balance between specific PTKs and tyrosine phosphatases. Whether pp60Sr (or isoenzymes thereof) represents the PTK mediating the tyrosine phosphorylation of specific substrates in response to fibrinogen cross-linking of GPIIb-lIIa has yet to be demonstrated.
pp60r" has been shown to be associated with another cytoskeleton-associated enzyme, P1-kinase.4t' We show that the p85 subunit Of P13-kinase is tyrosine-phosphorylated on activation of platelets with thrombin and that this phosphorylation is inhibited with genistein. P13-kinase phosphorylates inositol phospholipids on the third carbon of the inositol ring. In other systems, the activity of this enzyme has been connected to actin cytoskeleton reorganization.8 The mechanism mediating PI-kinase control on the actin cytoskeleton is not yet understood but is likely to involve the known interaction of actin-regulatory proteins with inositol phospholipids.4'142 It was shown that genistein also inhibits the genesis of membrane phosphoinositides such as phosphatidylinositol 4,5-diphosphate and prevents specific actin functions. 4 Together, these data suggest that genistein and AG-18 inhibition of GPlIb-IIIa activation may be mediated by the alteration of the metabolism of membrane inositol phospholipids after agonist stimulation of platelets and possibly by the perturbation of the actin cytoskeleton reorganization resulting from the abnormal metabolism of membrane phospholipids. SH3 domains, like the one found on p85-SH3. have been shown to target proteins to specific cellular sites, including actin filaments. 4 Accordingly, the distribution of p85-SH3 has been shown to match the distribution of filamentous actin.3 By immunoprecipitation. we found that p85-SH3 represents a major substrate for PTKs in thrombin-activated platelets. Although it is not known whether p85 -SH3 serves as a regulatory protein for the stability and/or the cross-linking of actin filaments, its strong tyrosine phosphorylation on platelet activation, its association with the actin cytoskeleton, and the presence of an SH3 domain within its sequence support the hypothesis that p85-SH3 plays an important role in linking the activity of agonist-activated PTKs and the actin cytoskeleton.
Although the present study provides new clues concerning the role of platelet PTKs in the expression of high-affinity fibrinogen receptors on the surface of activated platelets, key questions remain to be answered. (1) Which platelet tyrosine kinase activity/ substrate represents the limiting step slowing down the expression of activated GPIIb-IIIa upon addition of genistein? pp60U, with its high platelet concentration, focal adhesion subcellular distribution, and association with the actin cytoskeleton, appears as a likely candidate; however, transgenic mice lacking pp60`c did not display evidence of bleeding disorders nor any gross platelet abnormalities.46 Furthermore, it is noteworthy that the activity of isoenzymes of pp60`also present in platelets may actually be able to overcome the deficient pp60O function. Additional studies directly linking substrate phosphorylation to GPIIb-IIla activation are under way. (2) How does the actin cytoskeleton control the expression of activated GPIIb-IIIa? We observed that cytochalasin D, a known actin inhibitor, reduces by :50% the density of the binding site for soluble fibrinogen on the surface of maximally activated platelets (J.B. Addo, N. Faraday, D. Grigoryev, P.F. Bray, and P.J. Goldschmidt-Clermont, unpublished data). However the molecular reactions linking the actin cytoskeleton to GPIIb-IIIa activation and their putative regulation by platelet PTKs are still unknown. Further studies on the function of p85-SH3 in actin cytoskeleton organization may provide additional clues about these reactions.
Nevertheless, it appears that platelet PTKs are modulated at the two ends of the platelet-activating effector system. Clearly, agonist stimulation results in tyrosine phosphorylation of numerous platelet proteins, leading to cytoskeletal reorganization and changes in GPIIbIlla conformation that allows this receptor to bind soluble fibrinogen and thereby induce the aggregation of platelets. However, binding of fibrinogen to its receptor is also necessary for additional PTK activity.1"13 Since intricate regulation of activating signals and responsive effects is necessary for proper platelet function only at site where a platelet thrombus is needed, it is not surprising that PTKs are bidirectionally used in the signal-effector mechanism of platelet aggregation. Thus the PTK signaling system of platelets, with its dual regulation through integrins and agonist receptors, may serve to integrate stimuli and generate a thrombotic response only at sites where it is required, such as the damaged vessel wall. However, given the potential for positive reenforcement in such a signaling system, a perturbation in the tyrosine kinase/phosphatase balance may cause a lower threshold for a stimulus to lead to aggregation at sites and times where normally aggregation would not occur.
